Alternate Day Buprenorphine Administration, Phase IX - 14

University of Vermont

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000232

NIDA-06969-14

R01-06969-14

R01DA006969 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.

Sex: All

Ages: 22 to 51 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.